Loading clinical trials...
Loading clinical trials...
A Clinical Pharmacology Study of Multiple Doses of TA-7284 in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of TA-7284 orally administered once daily for 15 days (1 day followed by a 1 day washout period and then 14 consecutive days). Dose escalation design is utilized in this study, and dose escalation of TA-7284 will be starting with 25 mg (step 1). Subsequent doses of 100 mg (step 2), 200 mg (step 3) and 400 mg (step 4) are planned after review of the tolerance and PK of the previous step.
Age
25 - 65 years
Sex
ALL
Healthy Volunteers
No
P-One Clinic
Hachiōji, Tokyo-to, Japan
Start Date
June 1, 2008
Primary Completion Date
February 1, 2009
Completion Date
February 1, 2009
Last Updated
January 8, 2026
61
ACTUAL participants
TA-7284
DRUG
Placebo of TA-7284
DRUG
Lead Sponsor
Tanabe Pharma Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07433062